Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | FNTA | P49354 | 1/20 | 0.39 |
| ▸ | FNTB | P49356 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
| ▸ | FLT4 | P35916 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11534295 | 0.87 | KMT2A (0.66) | KMT2AMEN1ALDH1A1CYP19A1RORC | |
| SCHEMBL11531547 | 0.81 | KMT2A (0.77) | KMT2AMEN1CYP19A1CYP3A4RORC | |
| SCHEMBL8243325 | 0.80 | KMT2A (0.57) | KMT2AMEN1ALDH1A1CYP19A1RORC | |
| SCHEMBL4055564 | 0.80 | KMT2A (0.57) | KMT2AMEN1ALDH1A1CYP19A1RORC | |
| SCHEMBL4054111 | 0.75 | FNTA (0.59) | FNTAFNTBRORC | |
| SCHEMBL4905689 | 0.74 | KMT2A (0.53) | KMT2AMEN1ALDH1A1CYP19A1RORC | |
| SCHEMBL4909571 | 0.70 | KMT2A (0.48) | KMT2ALMNAMEN1ALDH1A1CYP19A1 | |
| Methyl Alcohol SCHEMBL27437903 | 0.69 | CYP1A2 (0.60) | KMT2AMEN1ALDH1A1GAAMAPT | |
| SCHEMBL27915998 | 0.67 | CYP1A2 (0.58) | KMT2ALMNAMEN1ALDH1A1GAA | |
| SCHEMBL2724772 | 0.67 | CYP1A2 (0.67) | KMT2ALMNAMEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579352-B2 | Retinoic acid mimetic anilides | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-08-25 | — | — | US | disclosed |
| US-20080058334-A1 | Retinoic Acid Mimetic Anilides | MABIRE DOMINIQUE | 2008-03-06 | — | — | US | disclosed |
| US-20070105858-A1 | RETINOIC ACID MIMETIC ANILIDES | MABIRE DOMINIQUE | 2007-05-10 | — | — | US | disclosed |
| US-7179825-B2 | Retinoic acid mimetic anilides | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-20 | — | — | US | disclosed |
| US-6936626-B2 | Retinoic acid mimetic anilides | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-08-30 | — | — | US | disclosed |
| US-20050165018-A1 | Retinoic acid mimetic anilides | MABIRE DOMINIQUE (FR) | 2005-07-28 | — | — | US | disclosed |
| EP-1037880-B1 | RETINOIC ACID MIMETIC ANILIDES | JANSSEN PHARMACEUTICA NV (BE) | 2004-06-30 | — | — | EP | disclosed |
| US-20020115653-A1 | Retinoic acid mimetic anilides | MABIRE DOMINIQUE (FR) | 2002-08-22 | — | — | US | disclosed |
| US-6319939-B1 | P-(HETEROCYCLIC METHYL)-SUBSTUTED ANILIDES ARE POTENT INHIBITORS OF THE RETINOIC ACID METABOLISM | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-11-20 | — | — | US | disclosed |
| EP-1037880-A1 | RETINOIC ACID MIMETIC ANILIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-09-27 | — | — | EP | disclosed |
| WO-1999029674-A1 | RETINOIC ACID MIMETIC ANILIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115653-A1 | Retinoic acid mimetic anilides | RXRA, RXRB, RXRG | KMT2A 2932/4885LMNA 1193/4885MEN1 4443/4885 |
| US-20050165018-A1 | Retinoic acid mimetic anilides | RXRA, RXRB, RXRG | KMT2A 3958/4885LMNA 1615/4885MEN1 3649/4885 |
| US-20080058334-A1 | Retinoic Acid Mimetic Anilides | RXRA, RXRB, RXRG | KMT2A 3811/4885LMNA 1674/4885MEN1 3705/4885 |
| US-20070105858-A1 | RETINOIC ACID MIMETIC ANILIDES | RXRA, RXRB, RXRG | KMT2A 3958/4885LMNA 1615/4885MEN1 3649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.